Equities

Surgical Science Sweden AB

Surgical Science Sweden AB

Actions
  • Price (SEK)120.40
  • Today's Change1.30 / 1.09%
  • Shares traded6.59k
  • 1 Year change-19.09%
  • Beta1.3101
Data delayed at least 15 minutes, as of Sep 19 2024 08:38 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Surgical Science Sweden AB is a Sweden-based company, which provides with virtual reality simulators for evidence based laparoscopic and endoscopic training. The systems comprise LapSim, EndoSim and TeamSim trainings. Each training combine graphics and cognitive instruction, imply navigation on touch screens and feature tactile feedback technology. The LapSim trainings consist of laparoscopic exercises that range from basic navigation to advanced suturing, the EndoSim endoscopic exercises range from functions of the scope handle and tube, to loop reduction. The TeamSim comprises procedure modules to train in a real world operation room environment and helps to build team communication skills in crisis and routine situations. The training systems are used by medical training centers and institutes worldwide for practice, validation and certification of students, surgeons, and medical doctors.

  • Revenue in SEK (TTM)838.25m
  • Net income in SEK197.72m
  • Incorporated1997
  • Employees265.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
BICO Group AB2.25bn-786.80m3.04bn828.00--1.05--1.35-11.15-15.2031.9241.790.36022.154.472,547,964.00-12.62---14.44--55.70---35.03--2.23-0.57050.397--6.09---1,889.33------
Medistim ASA519.02m100.58m3.20bn152.0031.768.6525.636.165.705.7029.4120.931.170.73196.343,542,250.0022.7122.9327.5928.5279.4978.2519.3820.642.40--0.026275.257.0010.06-8.9112.720.03314.87
Detection Technology Oyj-1.14tn-1.14tn3.20bn464.00--3.82----------5.03----------9.34--11.96--47.44--8.223.39--0.0053.455.292.027.55-18.03-14.88-9.55
COLTENE Holding AG2.88bn148.91m3.43bn1.19k23.092.8414.811.192.062.0639.8916.731.271.386.06198,668.906.5510.4811.7018.7464.9062.685.177.470.861910.180.342179.94-9.133.54-54.05-6.81-7.72-7.79
IVF Hartmann Holding AG1.84bn212.80m3.97bn298.0018.642.3314.042.157.357.3563.7258.840.87883.148.52502,947.4010.147.2912.068.9055.2153.2911.548.303.95--0.005852.16-1.792.0934.951.49-14.8326.82
Synektik SA1.64bn211.25m4.09bn164.0019.368.9817.352.499.329.3272.5420.092.0316.347.224,043,567.0026.0410.2441.6515.7926.6522.8612.858.851.2813.970.090947.00167.81--409.18------
RaySearch Laboratories AB (publ)1.13bn151.22m4.46bn403.0038.027.4810.633.954.414.4132.9122.410.57014.503.112,901,244.007.641.2911.801.8890.4890.5713.402.551.17--0.393769.0021.1610.26243.060.7648-1.31--
Ion Beam Applications SA5.29bn89.13m4.69bn1.84k50.734.4121.070.88690.26890.268915.993.090.77212.152.70234,517.101.301.556.014.3234.1935.231.692.380.63723.770.399264.8318.6710.74-250.40---8.06--
medmix AG5.79bn-21.72m4.83bn2.70k--0.85846.950.8344-0.05-0.0511.3511.300.47783.405.58180,474.00-0.09962.06-0.12272.4932.5836.38-0.20854.161.062.210.436167.701.991.40-97.41-64.3612.01--
Guerbet SA8.92bn270.94m5.17bn2.92k20.011.205.460.57921.801.8062.1529.970.79970.59835.80269,071.902.261.402.961.8678.0176.022.821.821.215.620.503557.824.30-0.0993158.05-12.615.23-10.07
Stratec SE2.91bn165.46m6.00bn1.46k36.242.3215.742.061.201.2021.0618.710.58411.365.23168,187.303.337.074.228.2027.0827.325.699.700.94014.720.397640.81-4.636.88-55.293.30-2.16-7.68
Surgical Science Sweden AB838.25m197.72m6.08bn265.0030.741.3223.807.253.873.8716.4390.020.16951.497.353,224,027.004.004.494.264.7868.5170.0623.5923.753.46--0.000.0010.0168.1424.47--38.57--
CellaVision AB726.40m145.06m6.34bn221.0043.748.5834.028.736.086.0830.4531.000.7831.766.663,185,965.0015.6415.3018.1818.2466.6269.0319.9719.981.99103.580.0574110.185.9413.1710.128.0030.458.45
Advanced Medical Solutions Group plc1.77bn150.20m7.44bn1.50k49.702.2724.574.210.0510.0510.60111.120.39771.704.91154,244.703.386.543.647.0654.4556.758.4914.826.80--0.270225.851.514.23-22.14-6.7115.6612.32
Paul Hartmann AG27.06bn675.82m8.01bn10.05k11.780.62064.190.29616.7616.76671.22318.251.181.995.45234,407.103.193.874.195.3458.0056.712.702.981.317.680.208242.751.802.12-21.37-18.495.952.71
Data as of Sep 19 2024. Currency figures normalised to Surgical Science Sweden AB's reporting currency: Swedish Krona SEK

Institutional shareholders

39.15%Per cent of shares held by top holders
HolderShares% Held
Handelsbanken Fonder ABas of 31 Aug 20243.85m7.55%
Capital Research & Management Co. (World Investors)as of 30 Jun 20243.27m6.41%
Fj�rde AP-fondenas of 31 May 20242.85m5.58%
Teknik Innovation Norden Fonder ABas of 31 May 20242.70m5.29%
Swedbank Robur Fonder ABas of 30 Aug 20241.96m3.84%
Joh. Berenberg, Gossler & Co. KG (Investment Management)as of 31 Aug 20231.55m3.04%
Montanaro Asset Management Ltd.as of 31 May 20241.09m2.14%
Amundi Asset Management SA (Investment Management)as of 04 Sep 20241.06m2.07%
Carnegie Fonder ABas of 31 Jul 20241.02m1.99%
Norges Bank Investment Managementas of 31 Dec 2023634.60k1.24%
More ▼
Data from 31 Dec 2022 - 11 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.